203 related articles for article (PubMed ID: 21809350)
21. [Pin1: a multi-talented peptidyl prolyl cis-trans isomerase and a promising therapeutic target for human cancers].
Marsolier J; Weitzman JB
Med Sci (Paris); 2014; 30(8-9):772-8. PubMed ID: 25174754
[TBL] [Abstract][Full Text] [Related]
22. Peptidyl-prolyl isomerase 1 (Pin1) serves as a coactivator of steroid receptor by regulating the activity of phosphorylated steroid receptor coactivator 3 (SRC-3/AIB1).
Yi P; Wu RC; Sandquist J; Wong J; Tsai SY; Tsai MJ; Means AR; O'Malley BW
Mol Cell Biol; 2005 Nov; 25(21):9687-99. PubMed ID: 16227615
[TBL] [Abstract][Full Text] [Related]
23. An immunohistochemical scoring system of prolyl isomerase Pin1 for predicting relapse of prostate carcinoma after radical prostatectomy.
Sasaki T; Ryo A; Uemura H; Ishiguro H; Inayama Y; Yamanaka S; Kubota Y; Nagashima Y; Harada M; Aoki I
Pathol Res Pract; 2006; 202(5):357-64. PubMed ID: 16516405
[TBL] [Abstract][Full Text] [Related]
24. Pin1 interacts with a specific serine-proline motif of hepatitis B virus X-protein to enhance hepatocarcinogenesis.
Pang R; Lee TK; Poon RT; Fan ST; Wong KB; Kwong YL; Tse E
Gastroenterology; 2007 Mar; 132(3):1088-103. PubMed ID: 17383430
[TBL] [Abstract][Full Text] [Related]
25. The metabolic crosstalk between PIN1 and the tumour microenvironment.
Caligiuri I; Vincenzo C; Asano T; Kumar V; Rizzolio F
Semin Cancer Biol; 2023 Jun; 91():143-157. PubMed ID: 36871635
[TBL] [Abstract][Full Text] [Related]
26. Peptidyl-prolyl cis/trans isomerase NIMA-interacting 1 associates with insulin receptor substrate-1 and enhances insulin actions and adipogenesis.
Nakatsu Y; Sakoda H; Kushiyama A; Zhang J; Ono H; Fujishiro M; Kikuchi T; Fukushima T; Yoneda M; Ohno H; Horike N; Kanna M; Tsuchiya Y; Kamata H; Nishimura F; Isobe T; Ogihara T; Katagiri H; Oka Y; Takahashi S; Kurihara H; Uchida T; Asano T
J Biol Chem; 2011 Jun; 286(23):20812-22. PubMed ID: 21454638
[TBL] [Abstract][Full Text] [Related]
27. The prolyl isomerase Pin1 interacts with a ribosomal protein S6 kinase to enhance insulin-induced AP-1 activity and cellular transformation.
Lee NY; Choi HK; Shim JH; Kang KW; Dong Z; Choi HS
Carcinogenesis; 2009 Apr; 30(4):671-81. PubMed ID: 19168580
[TBL] [Abstract][Full Text] [Related]
28. Multisite phosphorylation of Pin1-associated mitotic phosphoproteins revealed by monoclonal antibodies MPM-2 and CC-3.
Albert AL; Lavoie SB; Vincent M
BMC Cell Biol; 2004 Jun; 5():22. PubMed ID: 15171797
[TBL] [Abstract][Full Text] [Related]
29. Phosphorylation-specific prolyl isomerization: is there an underlying theme?
Wulf G; Finn G; Suizu F; Lu KP
Nat Cell Biol; 2005 May; 7(5):435-41. PubMed ID: 15867923
[TBL] [Abstract][Full Text] [Related]
30. The prolyl isomerase Pin1 enhances HER-2 expression and cellular transformation via its interaction with mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1.
Khanal P; Namgoong GM; Kang BS; Woo ER; Choi HS
Mol Cancer Ther; 2010 Mar; 9(3):606-16. PubMed ID: 20179161
[TBL] [Abstract][Full Text] [Related]
31. Cytosolic Aryl sulfotransferase 4A1 interacts with the peptidyl prolyl cis-trans isomerase Pin1.
Mitchell DJ; Minchin RF
Mol Pharmacol; 2009 Aug; 76(2):388-95. PubMed ID: 19439498
[TBL] [Abstract][Full Text] [Related]
32. PIN1 inhibits apoptosis in hepatocellular carcinoma through modulation of the antiapoptotic function of survivin.
Cheng CW; Chow AK; Pang R; Fok EW; Kwong YL; Tse E
Am J Pathol; 2013 Mar; 182(3):765-75. PubMed ID: 23333752
[TBL] [Abstract][Full Text] [Related]
33. Pin1 is overexpressed in oral squamous cell carcinoma and its levels correlate with cyclin D1 overexpression.
Miyashita H; Mori S; Motegi K; Fukumoto M; Uchida T
Oncol Rep; 2003; 10(2):455-61. PubMed ID: 12579289
[TBL] [Abstract][Full Text] [Related]
34. Pin1 induction in the fibrotic liver and its roles in TGF-β1 expression and Smad2/3 phosphorylation.
Yang JW; Hien TT; Lim SC; Jun DW; Choi HS; Yoon JH; Cho IJ; Kang KW
J Hepatol; 2014 Jun; 60(6):1235-41. PubMed ID: 24530597
[TBL] [Abstract][Full Text] [Related]
35. Pin1 as an anticancer drug target.
Xu GG; Etzkorn FA
Drug News Perspect; 2009 Sep; 22(7):399-407. PubMed ID: 19890497
[TBL] [Abstract][Full Text] [Related]
36. Effects of peptidyl-prolyl isomerase 1 depletion in animal models of prion diseases.
Legname G; Virgilio T; Bistaffa E; De Luca CMG; Catania M; Zago P; Isopi E; Campagnani I; Tagliavini F; Giaccone G; Moda F
Prion; 2018 Mar; 12(2):127-137. PubMed ID: 29676205
[TBL] [Abstract][Full Text] [Related]
37. Prolyl isomerase Pin1 stabilizes and activates orphan nuclear receptor TR3 to promote mitogenesis.
Chen HZ; Li L; Wang WJ; Du XD; Wen Q; He JP; Zhao BX; Li GD; Zhou W; Xia Y; Yang QY; Hew CL; Liou YC; Wu Q
Oncogene; 2012 Jun; 31(23):2876-87. PubMed ID: 22002310
[TBL] [Abstract][Full Text] [Related]
38. Phosphorylation-specific prolyl isomerase Pin1 as a new diagnostic and therapeutic target for cancer.
Finn G; Lu KP
Curr Cancer Drug Targets; 2008 May; 8(3):223-9. PubMed ID: 18473735
[TBL] [Abstract][Full Text] [Related]
39. Destabilization of KLF10, a tumor suppressor, relies on thr93 phosphorylation and isomerase association.
Hwang YC; Yang CH; Lin CH; Ch'ang HJ; Chang VHS; Yu WCY
Biochim Biophys Acta; 2013 Dec; 1833(12):3035-3045. PubMed ID: 23994618
[TBL] [Abstract][Full Text] [Related]
40. Prolyl isomerase Pin1 is highly expressed in Her2-positive breast cancer and regulates erbB2 protein stability.
Lam PB; Burga LN; Wu BP; Hofstatter EW; Lu KP; Wulf GM
Mol Cancer; 2008 Dec; 7():91. PubMed ID: 19077306
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
